Western blot analysis of extracts from HeLa cells 48 hours following transfection with 100 nM non-targeted SignalSilence® Control siRNA (Unconjugated). Protein expression levels are measured using Akt (pan) (C67E7) Rabbit mAb #4691 (left), β-Actin (13E5) Rabbit mAb #4970 (middle) or p44/42 MAPK (Erk1/2) (137F5) Rabbit mAb #4695 (right).
CST recommends transfection with 100 nM Control siRNA II 48 to 72 hours prior to cell lysis. For transfection procedure, follow protocol provided by the transfection reagent manufacturer. Please feel free to contact CST with any questions on use.
Each vial contains the equivalent of 50 transfections, which corresponds to a final siRNA concentration of 100 nM per transfection in a 24-well plate with a total volume of 300 μl per well.
SignalSilence® siRNA is supplied in RNAse-free water. Aliquot and store at -20ºC.
RNA interference is a method whereby gene expression can be selectively silenced through the delivery of double stranded RNA molecules into the cell. The introduction of a specific small interfering RNA (siRNA) strand prevents the translation of a target protein message through RNA degradation. SignalSilence® Control siRNA (Unconjugated) is a siRNA sequence that will not lead to the specific degradation of any cellular message. It is intended to serve as a negative control for experiments using targeted siRNA transfection. This duplex contains the same scrambled sequence used in SignalSilence® Control siRNA (Fluorescein Conjugate) #6201.
Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
SignalSilence is a registered trademark of Cell Signaling Technology, Inc.
Limited Use Label License, RNA interference: This product is licensed under European Patent 1144623 and foreign equivalents from Ribopharma AG, Kulmbach, Germany and is provided only for use in non-commercial research specifically excluding use (a) in drug discovery or drug development, including target identification or target validation, by or on behalf of a commercial entity, (b) for contract research or commercial screening services, (c) for the production or manufacture of siRNA-related products for sale, or (d) for the generation of commercial databases for sale to Third Parties. Information about licenses for these and other commercial uses is available from Ribopharma AG, Fritz-Hornschuch-Str. 9, D-95326 Kulmbach, Germany.